188 related articles for article (PubMed ID: 33143618)
21. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity.
Koide E; Mohardt ML; Doctor ZM; Yang A; Hao M; Donovan KA; Kuismi CC; Nelson AJ; Abell K; Aguiar M; Che J; Stokes MP; Zhang T; Aguirre AJ; Fischer ES; Gray NS; Jiang B; Nabet B
Chembiochem; 2023 Oct; 24(19):e202300141. PubMed ID: 37088717
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway.
Jiang WG; Ye L; Ji K; Frewer N; Ji J; Mason MD
Int J Oncol; 2012 Nov; 41(5):1635-42. PubMed ID: 22971748
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
24. Endothelial FAK as a therapeutic target in disease.
Infusino GA; Jacobson JR
Microvasc Res; 2012 Jan; 83(1):89-96. PubMed ID: 22008516
[TBL] [Abstract][Full Text] [Related]
25. New Insights on the Nuclear Functions and Targeting of FAK in Cancer.
Pomella S; Cassandri M; Braghini MR; Marampon F; Alisi A; Rota R
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216114
[TBL] [Abstract][Full Text] [Related]
26. Targeting focal adhesion kinase signaling in tumor growth and metastasis.
Schwock J; Dhani N; Hedley DW
Expert Opin Ther Targets; 2010 Jan; 14(1):77-94. PubMed ID: 20001212
[TBL] [Abstract][Full Text] [Related]
27. Targeting FAK in anticancer combination therapies.
Dawson JC; Serrels A; Stupack DG; Schlaepfer DD; Frame MC
Nat Rev Cancer; 2021 May; 21(5):313-324. PubMed ID: 33731845
[TBL] [Abstract][Full Text] [Related]
28. Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.
Roy-Luzarraga M; Hodivala-Dilke K
Clin Cancer Res; 2016 Aug; 22(15):3718-24. PubMed ID: 27262114
[TBL] [Abstract][Full Text] [Related]
29. FAK inhibitors as promising anticancer targets: present and future directions.
Mustafa M; Abd El-Hafeez AA; Abdelhafeez DA; Abdelhamid D; Mostafa YA; Ghosh P; Hayallah AM; A Abuo-Rahma GE
Future Med Chem; 2021 Sep; 13(18):1559-1590. PubMed ID: 34340532
[TBL] [Abstract][Full Text] [Related]
30. Signal transduction by focal adhesion kinase in cancer.
Zhao J; Guan JL
Cancer Metastasis Rev; 2009 Jun; 28(1-2):35-49. PubMed ID: 19169797
[TBL] [Abstract][Full Text] [Related]
31. Emerging roles of focal adhesion kinase in cancer.
Tai YL; Chen LC; Shen TL
Biomed Res Int; 2015; 2015():690690. PubMed ID: 25918719
[TBL] [Abstract][Full Text] [Related]
32. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
[TBL] [Abstract][Full Text] [Related]
33. Focal adhesion kinase as potential target for cancer therapy (Review).
Hao H; Naomoto Y; Bao X; Watanabe N; Sakurama K; Noma K; Motoki T; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Wang ZG; Takaoka M
Oncol Rep; 2009 Nov; 22(5):973-9. PubMed ID: 19787209
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study.
Sun Y; Wang R; Sun Y; Wang L; Xue Y; Wang J; Wu T; Yin W; Qin Q; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2022 Jul; 237():114373. PubMed ID: 35486993
[TBL] [Abstract][Full Text] [Related]
35. Evolving therapies and FAK inhibitors for the treatment of cancer.
Dunn KB; Heffler M; Golubovskaya VM
Anticancer Agents Med Chem; 2010 Dec; 10(10):722-34. PubMed ID: 21291406
[TBL] [Abstract][Full Text] [Related]
36. Targeting FAK in human cancer: from finding to first clinical trials.
Golubovskaya VM
Front Biosci (Landmark Ed); 2014 Jan; 19(4):687-706. PubMed ID: 24389213
[TBL] [Abstract][Full Text] [Related]
37. Focal adhesion kinase: Insight into its roles and therapeutic potential in oesophageal cancer.
Zhang Y; Liu S; Zhou S; Yu D; Gu J; Qin Q; Cheng Y; Sun X
Cancer Lett; 2021 Jan; 496():93-103. PubMed ID: 33038490
[TBL] [Abstract][Full Text] [Related]
38. Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
Levy A; Alhazzani K; Dondapati P; Alaseem A; Cheema K; Thallapureddy K; Kaur P; Alobid S; Rathinavelu A
Curr Cancer Drug Targets; 2019; 19(3):179-188. PubMed ID: 29984656
[TBL] [Abstract][Full Text] [Related]
39. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.
Kornberg LJ
Head Neck; 1998 Dec; 20(8):745-52. PubMed ID: 9790298
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
